Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Unicycive Therapeutics, Inc. securities, alleging misleading statements regarding the company's compliance with FDA manufacturing requirements and the regulatory prospects of its New Drug Application [1][5]. Group 1: Lawsuit Details - The class action lawsuit is filed for securities purchased between March 29, 2024, and June 27, 2025 [1]. - Investors who purchased Unicycive securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The lawsuit claims that Unicycive's readiness to meet FDA manufacturing compliance was overstated, along with the regulatory prospects of its oxylanthanum carbunate New Drug Application [5]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must file a motion with the court by October 14, 2025, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions for investors [4].

Core Viewpoint - The Law Offices of Frank R. Cruz is investigating America's Car-Mart, Inc. for potential violations of federal securities laws, indicating concerns over the company's financial practices and disclosures [1] Company Investigation - The investigation is initiated on behalf of investors who may have suffered losses due to the company's actions [1] - Car-Mart announced a delay in financial disclosures on July 15, 2025, which has raised red flags among investors [1]

Core Viewpoint - The article discusses a class action lawsuit against Dow Inc. for alleged violations of the Securities Exchange Act of 1934, with claims of misleading statements regarding the company's financial health and ability to manage macroeconomic challenges [1][3]. Group 1: Lawsuit Details - The class action lawsuit is titled Sarti v. Dow Inc., and it involves purchasers of Dow securities from January 30, 2025, to July 23, 2025, with a deadline of October 28, 2025, for lead plaintiff applications [1]. - Allegations include that Dow overstated its ability to handle macroeconomic and tariff-related challenges, and understated the negative impacts on its business, particularly regarding competitive pressures and declining global sales [3]. Group 2: Financial Performance - On June 23, 2025, BMO Capital downgraded Dow's stock from "Market Perform" to "Underperform," reducing the price target from $29.00 to $22.00 due to ongoing weakness in key markets [4]. - Dow reported a non-GAAP loss per share of $0.42 for Q2 2025, significantly worse than the expected loss of approximately $0.17 to $0.18, with net sales of $10.1 billion, a 7.3% year-over-year decline [5]. - Following the disappointing earnings report, Dow announced a dividend cut from $0.70 to $0.35 per share, citing the need for financial flexibility in a challenging macroeconomic environment, which led to a stock price drop of over 17% [5]. Group 3: Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Dow securities during the class period to seek lead plaintiff status, representing the interests of the class [6]. Group 4: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7]. - The firm has been recognized for securing significant monetary relief for investors, including the largest recovery in history of $7.2 billion in the Enron case [8].

Core Viewpoint - Capricor Therapeutics, Inc. is facing a class action lawsuit due to allegations of misleading investors regarding its lead cell therapy candidate, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [1][2]. Summary by Relevant Sections Allegations - The complaint claims that Capricor provided investors with overly positive information about deramiocel's potential to obtain a Biologics License Application (BLA) from the FDA while concealing adverse facts about its safety and efficacy data from the Phase 2 HOPE-2 trial [1]. - On July 11, 2025, Capricor announced it received a Complete Response Letter (CRL) from the FDA, denying the BLA due to insufficient evidence of effectiveness and the need for additional clinical data [1]. Stock Price Impact - Following the announcement of the CRL, Capricor's stock price dropped from $11.40 per share on July 10, 2025, to $7.64 per share on July 11, 2025, reflecting a significant decline in investor confidence [1]. Class Action Details - Shareholders who purchased shares during the class period from October 9, 2024, to July 10, 2025, are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for September 15, 2025 [2]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case [2]. Law Firm's Mission - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices, seeking recovery for losses incurred due to misleading statements or omissions by companies [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Quanex Building Products Corporation and its officers or directors, following disappointing financial results that led to a significant drop in stock price [1][3]. Financial Performance - On September 4, 2025, Quanex reported non-GAAP earnings per share of $0.69 for Q3 2025, which was $0.15 below consensus estimates [3]. - The company's stock price fell by $2.73, or 13.06%, closing at $18.18 per share on September 5, 2025, in response to the earnings miss [3]. Challenges Faced - The CEO of Quanex highlighted several challenges, including the need to re-segment the business, macroeconomic uncertainty, low consumer confidence, and operational issues related to the legacy Tyman window and door hardware business in Mexico [3].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud and unlawful business practices involving Fly-E Group, Inc. following a damaging report that led to a significant decline in the company's stock price [1][3]. Group 1: Investigation Details - Pomerantz LLP is representing investors of Fly-E Group, Inc. and is looking into whether the company and its officers or directors have engaged in securities fraud [1]. - The investigation was prompted by a report from The Bear Cave, which accused Fly-E of stock manipulation and being involved in a pump-and-dump scheme [3]. Group 2: Stock Performance - Following the publication of The Bear Cave report, Fly-E's stock price experienced a sharp decline over several consecutive trading sessions [3]. Group 3: Company Background - Fly-E Group, Inc. is under scrutiny for producing products that The Bear Cave claims endanger public safety in New York [3]. - Pomerantz LLP has a long history in corporate and securities class litigation, having recovered numerous multimillion-dollar damages awards for victims of securities fraud [4].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Coty Inc. following disappointing financial results and guidance [1][3]. Financial Performance - On August 20, 2025, Coty reported an unexpected loss for its full fiscal year 2025 and fourth quarter, which led to a significant decline in stock price [3][4]. - The Chief Financial Officer attributed sluggish sales to various factors, including value-seeking behavior among consumers, innovation fatigue, and changes in anti-theft and immigration policies [3]. Stock Market Reaction - Following the announcement of the financial results, Coty's stock price dropped by $1.05 per share, representing a 21.6% decline, closing at $3.81 per share on August 21, 2025 [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Axogen, Inc. and its officers or directors [1] Group 1: Company Developments - On August 25, 2025, Axogen announced that the FDA extended the PDUFA goal date for its Biologics License Application for Avance® Nerve Graft by three months to December 5, 2025 [3] - Following this announcement, Axogen's stock price decreased by $1.47 per share, or 9.04%, closing at $14.79 per share on the same day [3] Group 2: Legal Investigation - Pomerantz LLP is representing investors in investigating claims against Axogen for possible securities fraud or other unlawful business practices [1] - The firm has a long history in corporate, securities, and antitrust class litigation, having recovered numerous multimillion-dollar damages awards for victims of securities fraud [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Lineage, Inc. and its officers or directors [1] Group 1: Company Overview - Lineage, Inc. conducted its initial public offering on July 25, 2024, offering 56,882,051 shares at a price of $78.00 per share [3] - The company reported a total revenue of $1.29 billion for Q1 2025, reflecting a decrease of 2.7% compared to previous periods, attributed to more normal seasonal trends after elevated inventory levels [3] Group 2: Stock Performance - Following the Q1 2025 financial results announcement, Lineage's stock price dropped by $8.26 per share, or 14.62%, closing at $48.23 per share on April 30, 2025 [3]

Core Viewpoint - A securities fraud lawsuit has been filed against Lantheus Holdings Inc. and its executives, alleging that they misled investors regarding the performance and pricing of its key product, Pylarify, leading to significant stock price declines [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Lantheus and its executives provided false assurances about Pylarify's market leadership and pricing strength, while concealing competitive pressures and price erosion [2]. - Following the release of disappointing quarterly results in May and August 2025, Lantheus' stock experienced declines of over 23% and 28%, respectively, due to reduced revenue guidance and increased competition [2]. Group 2: Investor Eligibility - Investors who purchased Lantheus Holdings Inc. common stock between February 26, 2025, and August 5, 2025, and have experienced losses may be eligible to participate in the lawsuit, regardless of whether they sold their shares [3]. Group 3: Next Steps for Investors - The deadline for investors to seek appointment as lead plaintiff is November 10, 2025, and a class has not yet been certified [4]. - Investors are encouraged to contact Block & Leviton for more information on how to proceed if they have incurred losses [4]. Group 4: Whistleblower Information - Individuals with non-public information about Lantheus Holdings Inc. are encouraged to assist in the investigation or report to the SEC under the whistleblower program, potentially receiving rewards of up to 30% of any successful recovery [5]. Group 5: Firm Background - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [6].